These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer's Disease. Ketter N; Liu E; Di J; Honig LS; Lu M; Novak G; Werth J; LePrince Leterme G; Shadman A; Brashear HR J Prev Alzheimers Dis; 2016; 3(4):192-201. PubMed ID: 29199321 [TBL] [Abstract][Full Text] [Related]
6. Longitudinal Assessment of Amyloid-β Deposition by [18F]-Flutemetamol PET Imaging Compared With [11C]-PIB Across the Spectrum of Alzheimer's Disease. Hatashita S; Wakebe D; Kikuchi Y; Ichijo A Front Aging Neurosci; 2019; 11():251. PubMed ID: 31572167 [TBL] [Abstract][Full Text] [Related]
8. Metal protein attenuating compounds for the treatment of Alzheimer's dementia. Sampson EL; Jenagaratnam L; McShane R Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005380. PubMed ID: 24563468 [TBL] [Abstract][Full Text] [Related]
9. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE). Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of PiB visual interpretation with CSF Aβ and longitudinal SUVR in J-ADNI study. Okada Y; Kato T; Iwata K; Kimura Y; Nakamura A; Hattori H; Toyama H; Ishii K; Ishii K; Senda M; Ito K; Iwatsubo T; Ann Nucl Med; 2020 Feb; 34(2):108-118. PubMed ID: 31749127 [TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446 [TBL] [Abstract][Full Text] [Related]
12. Metal protein attenuating compounds for the treatment of Alzheimer's dementia. Sampson EL; Jenagaratnam L; McShane R Cochrane Database Syst Rev; 2012 May; 5(5):CD005380. PubMed ID: 22592705 [TBL] [Abstract][Full Text] [Related]
13. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging. Hatashita S; Wakebe D J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292 [TBL] [Abstract][Full Text] [Related]
14. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database. Ben Bouallègue F; Mariano-Goulart D; Payoux P; Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967 [TBL] [Abstract][Full Text] [Related]